freeze–thaw cycle raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
=== "Inflammaging" === "Inflammaging" refers a chronic, sterile, low-grade inflammation that develops with advanced age. It affects the start and progression of diseases that occur due to aging, e.g. type 2 diabetes. It occurs in the skin because when exposed to UV radiation, it damages the epidermal cells, which in turn causes inflammation to occur.
=== Radiological === Natural thorium decays very slowly compared to many other radioactive materials, and the emitted alpha radiation cannot penetrate human skin. As a result, handling small amounts of thorium, such as those in gas mantles, is considered safe, although the use of such items may pose some risks. Exposure to an aerosol of thorium, such as contaminated dust, can lead to increased risk of cancers of the lung, pancreas, and blood, as lungs and other internal organs can be penetrated by alpha radiation. Internal exposure to thorium leads to increased risk of liver diseases. The decay products of 232Th include more dangerous radionuclides such as radium and radon. Although relatively little of those products are created as the result of the slow decay of thorium, a proper assessment of the radiological toxicity of 232Th must include the contribution of its daughters, some of which are dangerous gamma emitters, and which are built up quickly following the initial decay of 232Th due to the absence of long-lived nuclides along the decay chain. As the dangerous daughters of thorium have much lower melting points than thorium dioxide, they are volatilised every time the mantle is heated for use. In the first hour of use large fractions of the thorium daughters 224Ra, 228Ra, 212Pb, and 212Bi are released. Most of the radiation dose by a normal user arises from inhaling the radium, resulting in a radiation dose of up to 0.2 millisieverts per use, about a third of the dose sustained during a mammogram.
== Medical uses == Insulin lispro is used to treat people with type 1 diabetes or type 2 diabetes. People doing well on short-acting insulin should not routinely be changed to insulin lispro, but may benefit from some advantages like flexibility and responsiveness.
In September 2024, Trump said the audience "went crazy" for him at the presidential debate the preceding week, although the debate had no audience. On October 6, 2024, The New York Times reported that Trump had maintained a far less active campaign schedule in 2024 than in 2016; the report added that Trump had held only 61 rallies through 2024, compared with 283 in all of 2016. In this same report, they analyzed Trump's speeches, writing, "with the passage of time, the 78-year-old former president's speeches have grown darker, harsher, longer, angrier, less focused, more profane and increasingly fixated on the past, according to a review of his public appearances over the years." The paper commented that Trump has lately seemed "confused, forgetful, incoherent or disconnected from reality" but that it does not get covered much because it is so common. It highlighted an average rally length of 82 minutes compared with 45 minutes in 2016, and a 13% increase in the use of all-or-nothing terms such as "always" and "never". It also found 32% more negative words than positive words compared with 21% in 2016, and a 69% increase in swear words. It cited experts who considered this increase in tangential speech and behavioral disinhibition the potential result of advancing age and cognitive decline. As of October 12, 2024, Trump had declined to release health information going back to 2015 when he first started running for president, despite a promise he made in August 2024 to release records from a recent examination.
=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.
Sources: en.wikipedia.org
Nevertheless, the successful synthesis of superheavy elements up to Z = 118 (oganesson) with up to 177 neutrons demonstrates a slight stabilizing effect around elements 110 to 114 that may continue in heavier isotopes, consistent with the existence of the island of stability.
Adal's headquarters were again relocated the following century, this time southward to Harar. From this new capital, Adal organised an effective army led by Imam Ahmad ibn Ibrahim al-Ghazi, (Ahmad "Gurey" or "Gran"; both meaning "the left-handed") and his closest top general and brother in law Garad Matan. Imam Ahmed clan is documented to be from the Geri Koombe, a sub clan of Darod. This 16th-century campaign is historically known as the Conquest of Abyssinia (Futuh al-Habash). During the war, Imam Ahmad pioneered the use of cannons supplied by the Ottoman Empire, which he imported through Zeila and deployed against Abyssinian forces and their Portuguese allies led by Cristóvão da Gama.
In some parts of Europe and India, Datura has been a popular poison for suicide and murder. From 1950 to 1965, the State Chemical Laboratories in Agra, India, investigated 2,778 deaths caused by ingesting Datura. A group called Thugs (practicers of thuggee) were reportedly devotees of an Indian religious cult made up of robbers and assassins who strangled or poisoned their victims in rituals devoted to the Hindu goddess Kali. They were alleged to employ Datura in many such poisonings, using it also to induce drowsiness or stupefaction, making strangulation easier. Datura toxins may be ingested accidentally by consumption of honey produced by several wasp species, including Brachygastra lecheguana, during the Datura blooming season. These semi-domesticated honey wasps apparently collect Datura nectar for honey production, which can lead to poisoning. The U.S. Centers for Disease Control and Prevention reported accidental poisoning resulting in hospitalization for a family of six who inadvertently ingested Datura used as an ingredient in stew. In some places around the world, such as India due to the Drug & Cosmetic Act 1940 & Rule 1995, buying, selling, or cultivating Datura plants is prohibited. Solanaceous tribes with a similar chemistry (i.e.
== Advantages == MIKES, as the name implies, is used for kinetic energy spectrometery. This means that certain criteria are needed to accomplish this. One such feature of MIKES is that it has high kinetic energy resolution and good angular resolution. This is due to the fact that MIKES has low accelerating voltage, around 3 kilo-volts. Another feature is that it has good differential pumping between the various regions of the instrument. In addition, MIKES has multiple systems for bringing in and/or overseeing collision gases or vapors and the ability to vary slit height and width. This prevents favoritism when determining kinetic energy distributions. Although common now, back in the 1970s, MIKES had a great computer compatibility that allowed for readily obtainable molecular structures.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.